obes
insulin
resist
primari
risk
factor
nonalcohol
fatti
liver
diseas
nafld
nafld
gener
exhibit
nonprogress
simpl
steatosi
howev
signific
subset
patient
progress
nonalcohol
steatohepat
nash
defin
presenc
steatosi
inflamm
hepatocyt
injuri
fibrosi
unfortun
approv
therapi
nafld
nash
therefor
therapeut
approach
urgent
need
niclosamid
us
food
drug
administr
fda
approv
anthelmint
drug
mediat
effect
uncoupl
oxid
phosphoryl
niclosamid
salt
form
niclosamid
ethanolamin
nen
niclosamid
piperazin
npp
shown
efficaci
murin
model
diet
induc
obes
character
attenu
promin
fatti
liver
diseas
phenotyp
improv
glucos
metabol
exact
mechan
underli
chang
remain
unclear
abil
uncoupl
oxid
phosphoryl
lead
increas
energi
expenditur
lipid
metabol
attenu
pka
mediat
glucagon
signal
liver
propos
unfortun
niclosamid
poor
water
solubl
lead
low
oral
bioavail
addit
mitochondri
uncoupl
activ
potenti
genotox
reduc
enthusiasm
clinic
use
recent
salt
form
niclosamid
nen
npp
demonstr
improv
oral
bioavail
retain
activ
suggest
develop
safer
effect
niclosamid
deriv
treatment
nafld
type
diabet
may
possibl
herein
explor
abil
seri
nsubstitut
phenylbenzamid
deriv
niclosamid
salicylanilid
chemotyp
attenu
hepat
steatosi
use
novel
phenotyp
vitro
model
fatti
liver
high
fat
dietf
mous
model
diet
induc
obes
studi
identifi
novel
compound
improv
preclin
properti
attenu
hepat
steatosi
vitro
vivo
compound
improv
drug
properti
may
use
plo
one
http
octob
open
access
citat
bhagat
ha
compton
sa
musso
dl
laudeman
cp
jackson
kmp
yi
ny
et
al
nsubstitut
phenylbenzamid
niclosamid
chemotyp
attenu
obes
relat
chang
high
fat
diet
fed
mice
plo
one
niclosamid
origin
develop
market
molluscicid
bayer
late
later
found
effect
antihelmint
use
clinic
decad
treat
intestin
tapeworm
infect
human
niclosamid
exert
antihelmint
effect
uncoupl
electron
transport
chain
atp
synthas
prevent
synthesi
atp
essenti
energi
molecul
cell
metabol
histor
use
mitochondri
uncoupl
human
avoid
due
low
therapeut
index
inde
best
known
mitochondri
uncoupl
dnp
increas
metabol
rate
stimul
loss
bodi
fat
associ
sever
toxic
includ
fatal
increas
bodi
temperatur
side
effect
may
overcom
liver
specif
target
dnp
shown
improv
therapeut
index
contrast
dnp
niclosamid
shown
rel
safe
deliv
singl
oral
dose
treat
intestin
cestod
infect
larg
due
poor
absorpt
gastrointestin
tract
high
plasma
protein
bind
significantli
limit
tissu
distribut
hand
also
limit
use
niclosamid
treat
diseas
system
exposur
requir
sever
studi
link
niclosamid
treatment
genotox
effect
measur
increas
sister
chromatid
exchang
sce
chromosom
aberr
ca
bone
marrow
cell
sperm
head
abnorm
mice
niclosamid
also
gener
point
mutat
salmonella
sp
clastogen
effect
human
lymphocyt
therefor
niclosamid
shown
rel
safe
singl
dose
unclear
chronic
treatment
niclosamid
would
lead
advers
effect
despit
possibl
concern
bioavail
genotox
interest
niclosamid
risen
dramat
recent
year
concomit
movement
toward
repurpos
approv
drug
inde
niclosamid
identifi
sever
screen
compound
broad
anticanc
activ
attribut
abil
regul
multipl
cellular
signal
pathway
frequent
dysregul
cancer
biolog
includ
nuclear
wntbeta
catenin
notch
niclosamid
also
propos
treatment
varieti
indic
includ
neuropath
pain
bacteri
viral
infect
metabol
diseas
also
identifi
niclosamid
high
throughput
screen
focus
identifi
modul
nonclass
peroxisom
biogenesi
potenti
allevi
symptom
dyslipidemia
metabol
syndrom
two
salt
form
niclosamid
improv
solubl
niclosamid
ethanolamin
salt
nen
niclosamid
piperazin
npp
shown
attenu
hepat
steatosi
glucos
metabol
murin
model
high
fat
diet
hfd
induc
obes
type
diabet
howev
mechan
niclosamid
benefici
effect
hepat
steatosi
wholebodi
glucos
metabol
remain
unclear
effect
may
mediat
mild
mitochondri
uncoupl
increas
energi
expenditur
increas
lipid
metabol
abil
niclosamid
nen
block
hepat
glucagon
signal
pathway
regardless
underli
mechan
compar
niclosamid
nen
npp
improv
oral
bioavail
retain
activ
mous
model
metabol
diseas
moreov
despit
mild
mitochondri
uncoupl
activ
well
toler
vivo
appear
exert
advers
effect
bodi
temperatur
knowledg
effect
salt
form
niclosamid
genotox
report
howev
anticip
salt
would
similarli
genotox
niclosamid
given
dramat
effect
niclosamid
hepat
steatosi
glucos
metabol
signific
interest
opportun
develop
novel
niclosamid
deriv
improv
efficaci
translat
potenti
sever
new
niclosamid
deriv
describ
diverg
activ
atp
homeostasi
wnt
pathway
suggest
niclosamid
deriv
lack
uncoupl
activ
made
improv
pharmacolog
properti
treat
differ
indic
herein
explor
seri
phenylbenzamid
deriv
salicylanilid
chemotyp
evalu
potenti
nafld
therapeut
use
vitro
vivo
model
hepat
steatosi
obes
puriti
benzamid
use
studi
confirm
hplc
agil
technolog
seri
found
pure
structur
confirm
mass
spectrometri
agil
technolog
quadrupol
hnmr
varian
mhz
found
consist
desir
product
commerci
avail
reagent
synthesi
describ
use
receiv
full
descript
synthet
protocol
molecul
describ
herein
avail
support
inform
nonneoplast
human
hepatocyt
cell
kindli
provid
stanley
lemon
univers
north
carolina
chapel
hill
maintain
dulbecco
modifi
eagl
medium
dmem
contain
mgl
glucos
lglutamin
life
technolog
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
thermo
fisher
scientif
mm
sodium
pyruv
thermo
fisher
scientif
previous
describ
cell
commerci
avail
short
tandem
repeat
str
profil
exist
databas
therefor
cell
authent
use
str
profil
genetica
compar
refer
databas
atcc
dsmz
cellasuaru
exclud
contamin
known
cell
line
human
embryon
kidney
hek
cell
obtain
atcc
manassa
va
maintain
complet
dmem
life
technolog
thermo
fisher
scientif
contain
fb
atlanta
biolog
co
human
liver
cell
atcc
also
obtain
atcc
maintain
complet
dmem
contain
fetal
bovin
serum
co
hepat
de
novo
lipogenesi
dnl
assay
develop
format
use
polydlysin
coat
black
optic
bottom
plate
polym
base
greiner
bioon
cell
harvest
count
use
vicel
xr
beckmancoult
seed
cell
per
well
cultur
media
h
media
remov
replac
fresh
cultur
media
biomek
nx
workstat
use
head
use
compound
addit
compound
test
quadrupl
concentr
rang
compound
first
dilut
format
plate
compound
dmso
directli
dispens
well
cell
plate
therebi
avoid
serial
dilut
step
final
dmso
concentr
hour
media
compound
remov
well
use
biomek
nx
workstat
except
minimum
signal
control
receiv
dmem
well
receiv
mm
stock
solut
contain
mixtur
insulin
lxr
agonist
prepar
dmem
well
give
final
concentr
insulin
cell
cultur
addit
hour
induc
de
novo
lipid
synthesi
upon
complet
media
remov
well
use
multichannel
pipett
cell
wash
phosphatebuff
salin
pb
prior
fixat
stain
immedi
follow
pb
wash
step
neutralbuff
formalin
nbf
contain
cellperman
nuclear
stain
ad
well
incub
co
minut
cell
wash
pb
hc
lipidtox
green
neutral
lipid
stain
thermosfish
appli
follow
dilut
pb
cell
incub
lipidtox
stain
room
temperatur
min
plate
seal
aluminum
foil
use
thermoabgen
plate
sealer
imag
use
cellinsight
high
content
screen
hc
platform
within
hour
process
olympu
lucplanfln
microscop
object
use
camera
bin
lead
per
pixel
resolut
lipidtox
green
stain
use
demarc
lipid
content
excit
use
nm
excit
led
hoechst
signal
nucleic
acid
excit
use
nm
led
imag
analysi
perform
use
open
sourc
cell
profil
softwar
use
cell
identif
featur
extract
data
tabul
twopass
highlow
threshold
process
use
identifi
nuclei
cytoplasm
channel
pipelin
develop
automat
identifi
nuclei
cytoplasm
featur
extract
cell
level
data
analyz
sa
cari
nc
hundr
primari
featur
per
cell
gener
base
intens
measur
morpholog
characterist
employ
partial
least
squar
pl
regress
analysi
method
identifi
import
cellular
featur
reduc
data
set
singl
score
system
toler
outlier
hepat
steatosi
typic
steatot
fingerprint
score
repres
approxim
individu
featur
includ
lipid
droplet
count
intens
size
cellular
morpholog
data
normal
percent
control
npc
use
equat
npc
x
c
c
c
x
raw
valu
c
plate
mean
posit
control
cplate
mean
neg
control
valu
averag
compound
identifi
posit
hit
reduc
steatot
phenotyp
rel
maximum
signal
control
dose
respons
z
valu
calcul
use
z
p
n
p
n
mean
standard
deviat
p
posit
n
neg
control
oxygen
consumpt
rate
experi
perform
zenbio
inc
rtp
nc
cell
stabli
transduc
human
transport
plate
blackwal
microclear
plate
greinerbioon
cell
per
well
growth
medium
cell
incub
overnight
allow
attach
growth
medium
remov
replac
assay
medium
contain
compound
dilut
four
concentr
compound
prepar
transfer
empti
well
control
well
contain
assay
medium
assay
medium
contain
ptrifluoromethoxyphenylhydrazon
fccp
ten
mitoxpress
xtra
reagent
ad
test
well
prewarm
miner
oil
overlaid
well
creat
seal
plate
immedi
read
fluostar
omega
bmg
use
dual
read
time
resolv
fluoresc
trf
hour
measur
taken
everi
minut
use
excit
emiss
wavelength
respect
lifetim
analysi
two
measur
per
well
taken
delay
window
delay
window
background
trf
valu
subtract
read
ratiometr
analysi
perform
determin
chang
lifetim
fluoresc
signal
lifetim
ln
delay
w
fluoresc
window
valu
time
point
lifetim
slope
calcul
use
lifetim
measur
time
data
present
mean
standard
error
se
differ
control
dmso
compound
treat
well
analyz
use
student
ttest
valu
consid
statist
signific
cell
seed
well
plate
cultur
confluenc
cell
fed
new
media
hour
addit
compound
reduc
basal
ampk
phosphoryl
compound
deliv
fresh
media
hour
harvest
cell
western
blot
analysi
protein
lysat
immunoblot
prepar
suspend
cell
pellet
lysi
buffer
mm
trishcl
ph
proteas
phosphatas
inhibitor
cocktail
sigmaaldrich
benzonas
nucleas
plu
triton
shake
hour
follow
centrifug
g
min
microfug
tube
supernat
collect
protein
concentr
determin
use
biorad
dc
protein
assay
protein
boil
load
buffer
subject
sd
page
invitrogen
follow
western
analys
use
follow
primari
antibodi
phosphoamp
activ
protein
kinas
ampk
thr
cell
signal
total
ampk
cell
signal
fatti
acid
synthas
fa
cell
signal
carbon
anhydras
santa
cruz
biotechnolog
secondari
antibodi
irdy
infrar
antibodi
licor
bioscienc
lincoln
ne
antigoat
igg
antirabbit
igg
use
dilut
scan
analyz
quantif
blot
perform
use
odyssey
infrar
imag
system
licor
bioscienc
western
blot
mous
liver
tissu
lysat
perform
describ
previous
phosphoryl
ampk
trfret
assay
kit
purchas
cisbio
bedford
cell
trypsin
harvest
count
use
countess
ii
fl
autom
cell
counter
thermo
fisher
scientif
cell
seed
polydlysin
coat
black
optic
plate
concentr
cell
per
well
growth
medium
media
remov
replac
fresh
growth
media
contain
compound
five
concentr
compound
prepar
rang
appli
column
cell
plate
control
well
contain
dmso
column
respons
control
column
respons
control
final
dmso
concentr
cell
cultur
hour
cell
lyse
lysi
buffer
minut
room
temperatur
accord
assay
protocol
follow
lysi
lysat
transfer
white
well
small
volum
assay
plate
antibodi
dye
ad
per
assay
protocol
follow
overnight
incub
quantit
perform
pherastar
bmg
use
htrf
protocol
excit
wavelength
emiss
wavelength
ratio
emiss
spectra
assess
well
individu
averag
triplic
sampl
data
present
mean
ratio
se
differ
control
dmso
compound
treat
well
analyz
use
twoway
anova
dunnett
post
hoc
test
valu
p
consid
signific
human
mous
liver
microsom
purchas
corn
lot
number
respect
three
experi
perform
microsom
nadph
microsom
without
nadph
heat
inactiv
microsom
without
nadph
phosphat
buffer
contain
magnesium
chlorid
reaction
initi
addit
experiment
compound
verapamil
control
incub
indic
time
point
sampl
remov
stop
addit
volum
cold
acetonitril
intern
standard
alprazolam
labetalol
ketoprofen
sampl
centrifug
g
minut
aliquot
subsequ
dilut
ultrapur
water
analyz
lcmsm
use
shimadzu
corpor
lc
system
coupl
shimadzu
tripl
quad
mass
spectromet
esi
interfac
lc
system
use
water
xselect
hss
x
mm
column
elut
one
two
method
use
mobil
phase
water
formic
acid
b
acetonitril
formic
acid
evalu
pharmacokinet
profil
oral
po
intraven
iv
administr
rout
use
old
spragu
dawley
rat
weigh
approxim
n
per
studi
group
compound
administ
cremophor
el
water
iv
pb
po
dose
formul
perform
room
temperatur
anim
fast
overnight
prior
dose
refe
approxim
hour
dose
po
blood
collect
preand
drug
deliveri
transfer
bd
vacutain
plastic
blood
collect
tube
iv
sampl
collect
preinject
post
inject
blood
sampl
centrifug
g
minut
obtain
plasma
plasma
sampl
store
prior
analysi
thaw
analyz
lcmsm
method
pharmacokinet
calcul
perform
use
winnolin
phoenix
version
iv
administr
c
auc
last
auc
inf
mrt
cl
vss
number
point
regress
determin
po
administr
c
max
max
auc
inf
auc
last
f
number
point
regress
determin
data
report
mean
standard
deviat
ame
assay
use
evalu
genotox
strain
salmonella
typhimurium
tryptophan
auxotroph
strain
escherichia
coli
uvra
use
detect
revers
mutat
histidin
locu
presenc
absenc
exogen
metabol
activ
aroclor
induc
rat
liver
assay
conduct
presenc
absenc
mixtur
along
neg
control
dmso
posit
control
posit
control
chemic
activ
experi
sodium
azid
sa
nmethyln
nitronnitrosoguanidin
mnng
uvra
compound
test
well
compound
consid
posit
induc
increas
mean
number
revert
coloni
compar
neg
control
dmso
rodent
studi
describ
manuscript
approv
north
carolina
central
univers
institut
anim
care
use
committe
protocol
number
mice
purchas
jackson
laboratori
bar
harbor
singli
hous
constant
temperatur
lightdark
cycl
hour
day
anim
care
assess
accredit
laboratori
anim
care
aalac
accredit
facil
biomed
biotechnolog
research
institut
north
carolina
central
univers
experiment
protocol
approv
institut
anim
care
use
committe
fiftyfour
old
male
diet
induc
obes
dio
mice
allow
acclimat
week
prior
initi
studi
mice
access
water
kcal
fat
diet
research
diet
ad
libitum
anim
inject
daili
intraperiton
ip
inject
solut
dmso
alon
compound
indic
dose
dissolv
dmso
previous
describ
six
wildtyp
mice
fed
standard
chow
diet
use
control
remain
untreat
day
treatment
mice
human
euthan
entir
liver
excis
liver
color
immedi
evalu
liver
tissu
collect
lower
portion
left
lobe
formalin
fix
formalinfix
paraffinembed
liver
tissu
section
thick
stain
hematoxylin
eosin
h
e
use
evalu
chang
liver
histolog
h
e
stain
liver
section
scan
total
magnif
use
aperio
scanscop
slide
scanner
histolog
examin
perform
use
standard
histolog
score
system
nafld
degre
steatosi
grade
follow
fatti
infiltr
classifi
microvesicular
macrovesicular
mix
locat
zone
azon
record
imag
analysi
use
autom
steatosi
phenotyp
use
custom
imageprocess
algorithm
data
analysi
pipelin
creat
use
cell
profil
softwar
algorithm
automat
identifi
analyz
macroand
micro
vesicular
steatosi
base
size
shape
locat
lipid
droplet
intensitytextur
cytoplasm
stain
respect
analyz
data
use
partial
least
squar
pl
regress
analysi
gener
multivari
score
system
softwar
sa
cari
nc
pl
score
system
take
tissu
averag
macrosteatosi
microsteatosi
score
normal
tissu
area
multipli
respect
import
factor
sum
overal
score
hepat
steatosi
use
sham
anim
control
steatosi
score
statist
analysi
perform
use
jmp
graphpad
data
present
mean
se
differ
sham
compound
treat
group
analyz
use
student
ttest
valu
consid
statist
signific
de
novo
lipogenesi
dnl
import
contributor
pathogenesi
nafld
abnorm
elev
rate
higher
patient
condit
compar
bodi
mass
index
match
control
also
upregul
peopl
metabol
disord
includ
obes
dnl
govern
varieti
lipogen
transcript
factor
includ
liver
x
receptor
lxr
sterol
regulatori
elementbind
carbohydr
respons
element
bind
protein
chrebp
liver
transcript
activ
insulin
lead
activ
gene
involv
fatti
acid
triglycerid
synthesi
lxr
also
regul
lipogen
gene
requir
transcript
control
insulin
base
previou
studi
show
effect
niclosamid
salt
form
nen
npp
hepat
steatosi
sought
establish
cellbas
diseas
model
nafld
use
insulin
lxr
agonist
stimul
de
novo
hepat
lipid
accumul
studi
effect
relat
nsubstitut
phenylbenzamid
steatosi
nonneoplast
human
hepatocyt
cell
line
follow
stimul
lipid
accumul
cell
fix
label
hc
lipidtox
green
neutral
lipid
stain
cellperm
nuclear
counterstain
imag
label
cell
captur
cellom
thermofish
autom
highcont
microscop
use
olympu
object
imag
unstimul
stimul
cell
collect
autom
imag
analysi
perform
tabul
cellular
lipid
content
green
channel
total
cell
count
blue
channel
fig
show
neg
control
stimul
insulin
hour
posit
control
stimul
result
segment
identif
nuclei
white
line
cell
blue
line
lipid
droplet
green
line
use
highcont
imag
analysi
unstimul
posit
control
shown
fig
repres
basal
lipid
content
cell
insulin
stimul
neg
control
cell
accumul
signific
lipid
droplet
develop
steatot
phenotyp
shown
fig
phenotyp
amelior
niclosamid
demonstr
lipid
droplet
accumul
panel
f
develop
custom
imageprocess
algorithm
data
analysi
pipelin
base
open
sourc
cell
profil
softwar
platform
enabl
accur
quantit
steatot
phenotyp
key
cellular
featur
includ
identif
nuclei
cell
boundari
lipid
droplet
contain
therein
region
accur
identifi
featur
extract
cell
combin
respons
factor
data
output
assay
gener
hundr
primari
featur
per
cell
includ
intens
measur
morpholog
characterist
subcellular
featur
aggreg
phenotyp
fingerprint
steatot
phenotyp
featur
extract
identifi
import
cellular
featur
chang
respons
lipid
accumul
includ
cell
number
total
lipid
intens
lipid
spot
count
lipid
spot
size
use
partial
least
squar
pl
regress
analysi
gener
multivari
score
system
critic
featur
ultim
goal
data
reduct
toward
singl
robust
score
system
captur
steatot
phenotyp
toler
outlier
effect
pl
score
system
take
wellaverag
featur
multipli
respect
import
factor
sum
overal
score
well
score
normal
perplat
effect
use
unstimul
control
effect
stimul
dmso
vehicl
effect
control
bioimag
platform
consist
yield
averag
zprime
factor
moreov
assay
includ
intern
measur
evalu
vitro
liver
toxic
base
nuclei
count
featur
use
hoechst
channel
compound
consid
toxic
cell
count
fell
vehicl
control
valu
cell
number
effort
valid
phenotyp
assay
better
understand
clinic
relev
dnl
assay
test
niclosamid
metforminth
classic
antidiabet
drug
triacsin
ca
potent
inhibitor
long
fatti
acyl
coa
synthetas
abil
attenu
steatosi
phenotyp
platform
triacsin
c
niclosamid
inhibit
steatot
phenotyp
concentr
depend
manner
albeit
differ
potenc
fig
triacsin
c
niclosamid
reduc
steatosi
respect
conclud
result
high
content
imag
cellbas
diseas
model
hepat
steatosi
provid
novel
method
evalu
compound
abil
improv
hepat
steatosi
either
suppress
de
novo
lipid
synthesi
stimul
downstream
catabol
pathway
includ
fatti
acid
oxid
cellbas
efficaci
assay
detect
therapeuticallyrelev
improv
metabol
phenotyp
cellperm
compound
aid
priorit
compound
develop
potenti
therapeut
base
dnl
assay
result
use
platform
systemat
explor
phenylbenzamid
chemotyp
goal
identifi
compound
retain
robust
hepat
lipid
lower
activ
improv
druglik
properti
previous
mention
nitro
group
niclosamid
impart
poor
solubl
limit
oral
bioavail
potenti
livertox
moieti
initi
goal
improv
absorpt
characterist
experiment
compound
replac
aromat
nitro
group
electron
withdraw
ester
acid
moieti
furthermor
strong
electron
withdraw
nitro
group
also
associ
increas
protonophor
activ
believ
underli
mechan
niclosamid
affect
atp
synthesi
oxid
phosphoryl
therefor
hypothes
remov
nitro
group
may
disrupt
mitochondri
uncoupl
activ
niclosamid
also
aim
improv
potenc
investig
balanc
polar
hydrophil
carboxyl
acid
group
nonpolar
lipophil
substitu
salicycl
acid
portion
molecul
replac
chloro
group
alkyl
group
use
sar
strategi
synthes
test
nsubstitut
phenylbenzamid
deriv
dnl
assay
tabl
newli
synthes
compound
test
dose
respons
format
use
dilut
rang
compound
consid
activ
exhibit
effect
dnl
assay
display
sigmoid
dose
respons
test
compound
design
activ
fig
show
data
repres
nsubstitut
phenylbenzamid
class
predict
solubl
ph
clogp
clogd
valu
ic
deriv
shown
compar
ic
compound
niclosamid
found
significantli
potent
niclosamid
ic
valu
respect
contrast
far
least
potent
compound
ic
note
sever
compound
includ
produc
invers
concentr
curv
compound
greater
predict
solubl
compar
niclosamid
log
particular
predict
solubl
best
valu
log
follow
log
log
log
fig
calcul
clogp
valu
measur
hydrophob
also
shown
fig
except
compound
lipophil
compar
niclosamid
except
clogp
valu
niclosamid
salt
form
uncoupl
mitochondri
oxid
phosphoryl
character
induct
cellular
oxygen
consumpt
rate
ocr
identifi
number
phenylbenzamid
vitro
activ
attenu
hepat
steatosi
phenotyp
next
explor
effect
structur
chang
ocr
use
mitoxpress
xtraoxygen
consumpt
assay
kit
luxcel
bioscienc
due
low
basal
respir
rate
cell
ocr
measur
cell
line
stabli
express
human
posit
control
includ
carbonyl
cyanideptrifluoromethoxyphenylhydrazon
fccp
wellknown
uncoupl
oxid
phosphoryl
niclosamid
increas
ocr
cell
compar
dmso
control
test
alongsid
select
phenylbenzamid
deriv
fig
interestingli
phenylbenzamid
deriv
produc
vari
respons
ocr
assay
rang
chang
respir
signific
chang
niclosamid
show
dose
depend
increas
ocr
wherea
significantli
elev
contrast
phenylbenzamid
deriv
significantli
decreas
ocr
concentr
ampk
metabol
sensor
maintain
cellular
energi
suppli
valid
chang
lipid
metabol
cellular
respir
evalu
phosphoampk
niclosamid
analog
attenu
obes
relat
chang
high
fat
diet
fed
mice
pampk
level
western
blot
cell
treat
phenylbenzamid
deriv
compound
screen
use
known
uncoupl
niclosamid
fccp
posit
control
fig
compound
show
activ
rescreen
confirm
neg
fig
compound
stimul
phosphoryl
ampk
evalu
cell
use
cisbio
pampk
trfret
assay
dose
respons
fig
western
blot
analysi
p
niclosamid
analog
attenu
obes
relat
chang
high
fat
diet
fed
mice
ampk
cell
show
acid
form
stimul
phosphoryl
ampk
peak
correspond
ribosom
protein
invers
regul
fig
also
stimul
phosphoryl
ampk
albeit
differ
potenc
fig
compound
show
detect
chang
pampk
level
conclud
compound
littl
effect
oxygen
consumpt
rate
also
littl
effect
phosphoryl
ampk
howev
appear
stimul
phosphoryl
ampk
without
chang
oxygen
consumpt
compound
appear
stimul
phosphoryl
ampk
increas
oxygen
consumpt
rate
stimul
phosphoryl
ampk
highest
concentr
effect
oxygen
consumpt
rate
concentr
test
metabol
stabil
paramount
develop
oral
therapeut
nafldnash
test
vitro
intrins
clearanc
select
compound
human
liver
microsom
hlm
mous
liver
microsom
mlm
use
verapamil
control
poor
stabil
tabl
verapamil
perform
expect
assess
percentag
initi
concentr
compound
remain
hour
remain
min
hlm
mlm
prepar
respect
gener
compound
exhibit
good
microsom
stabil
anticip
compound
stabl
mlm
rel
hlm
exhibit
greatest
metabol
stabil
initi
concentr
remain
minut
hlm
mlm
respect
similarli
start
materi
remain
minut
hlm
mlm
respect
hand
stabl
mlm
hlm
initi
concentr
remain
minut
tabl
compound
report
found
complet
degrad
min
remain
hlm
remain
mlm
next
explor
pharmacokinet
profil
spragu
dawley
rat
follow
oral
iv
administr
four
compound
previous
exhibit
good
microsom
stabil
previou
studi
oral
dose
niclosamid
rat
lead
peak
plasma
concentr
cmax
halflif
hour
three
four
phenylbenzamid
deriv
significantli
improv
oral
bioavail
compar
niclosamid
inde
singl
oral
dose
formul
pb
gave
peak
plasma
concentr
rat
halflif
hour
correl
f
similarli
oral
administr
led
peak
plasma
concentr
halflif
f
reach
peak
halflif
result
f
tabl
therefor
select
modifi
phenylbenzamid
function
group
abl
significantli
improv
bioavail
time
niclosamid
halfliv
rat
hour
respect
greater
hour
report
nen
mice
valu
remain
high
enough
suitabl
advanc
clinic
develop
result
sever
studi
indic
niclosamid
may
damag
dna
herein
use
ame
assay
assess
abil
four
phenylbenzamid
analog
induc
dna
damag
bacteria
niclosamid
induc
increas
mean
number
revert
coloni
presenc
mix
strain
tabl
mean
valu
revert
coloni
exceed
neg
control
rang
contrast
niclosamid
induc
increas
uvra
increas
concentr
test
tabl
niclosamid
also
exhibit
signific
cytotox
uvra
well
presenc
absenc
mix
well
strain
concentr
well
presenc
mix
well
absenc
mix
contrast
induc
increas
uvra
increas
dose
level
test
mean
number
revert
coloni
cytotox
exhibit
concentr
rel
neg
control
tabl
similarli
exhibit
increas
mean
number
revert
coloni
strain
concentr
test
compar
neg
control
tabl
howev
cytotox
exhibit
highest
concentr
strain
presenc
absenc
mix
contrast
studi
conclud
niclosamid
posit
ame
assay
wherea
neg
data
ambigu
compar
therapeut
effect
niclosamid
newli
synthes
analog
hepat
steatosi
use
induc
obes
dio
mous
diseas
model
type
diabet
extens
fatti
liver
diseas
mice
exhibit
massiv
hyperglycemia
obes
hepat
steatosi
insulin
resist
dyslipidemia
proinflammatori
cytokin
singli
hous
old
male
mice
rais
fat
diet
test
glucos
sensit
use
glucos
toler
test
gtt
anim
treat
niclosamid
vehicl
day
gtt
perform
compar
sham
anim
blood
glucos
level
minut
niclosamid
treat
anim
exhibit
statist
signific
reduct
glucos
level
fig
overal
niclosamid
reduc
plasma
glucos
level
approxim
period
fig
consist
previou
studi
show
improv
glucos
metabol
mous
model
metabol
diseas
next
measur
bodi
weight
chang
hfdfed
anim
prior
treatment
niclosamid
phenylbenzamid
deriv
day
prior
sacrific
time
anim
includ
sham
lost
weight
howev
treat
anim
lost
significantli
weight
compar
sham
anim
trial
tabl
treat
anim
also
lost
weight
loss
fail
reach
signific
p
statist
signific
differ
observ
sham
treatment
group
attempt
understand
mechanist
basi
chang
evalu
sever
pathway
dysregul
liver
hfdfed
mice
western
blot
analysi
given
correl
ampk
lipid
metabol
explor
possibl
niclosamid
activ
ampk
vivo
old
male
mice
rais
fat
diet
treat
niclosamid
day
via
daili
ip
inject
dmso
vehicl
uvra
sham
anim
administ
vehicl
schedul
determin
ampk
activ
vivo
respons
niclosamid
measur
pampk
phosphoryl
site
absolut
requir
ampk
activ
wide
use
ampk
field
surrog
kinas
activ
ampk
significantli
upregul
vivo
low
high
dose
niclosamid
fig
also
observ
signific
reduct
express
fatti
acid
synthas
fa
highest
concentr
niclosamid
fig
interest
note
previou
studi
also
identifi
carbon
anhydraseiii
caiii
hepat
protein
alter
hfd
feddio
mice
regul
niclosamid
treatment
posit
correl
extent
ectop
lipid
accumul
also
analyz
effect
pampk
fa
caiii
use
western
blot
analysi
studi
show
treatment
hfd
feddio
mice
day
also
stimul
phosphoryl
ampk
reduc
fa
caiii
protein
level
compar
sham
mice
fig
niclosamid
salt
form
nen
npp
shown
improv
hepat
steatosi
mous
model
metabol
diseas
compar
abil
novel
benzamid
improv
hepat
steatosi
fat
fed
dio
mice
treat
niclosamid
one
deriv
day
liver
immedi
examin
chang
gross
morpholog
except
liver
treat
anim
liver
treat
anim
show
improv
morpholog
within
day
liver
treat
anim
becam
darker
red
color
compar
sham
hfdfed
anim
visibl
lighter
tan
color
due
ectop
fat
accumul
histolog
analysi
tabl
niclosamid
analog
attenu
hepat
steatosi
high
fat
diet
fed
mice
old
hfdfed
mice
deliv
vehicl
compound
daili
ip
day
bodi
weight
measur
score
greasi
coat
phenotyp
perform
prior
follow
treatment
histolog
analysi
h
e
stain
liver
section
analyz
steatosi
steatosi
score
report
lower
left
lobe
treat
mice
show
improv
macroand
microsteatosi
within
day
except
mice
treat
pattern
steatosi
also
alter
anim
treat
niclosamid
almost
complet
clear
steatosi
notabl
clearanc
lipid
observ
predomin
treat
anim
repres
imag
liver
tissu
mice
fed
standard
chow
fat
diet
hfdfed
anim
hfd
treat
niclosamid
sham
anim
shown
fig
steatosi
score
use
evalu
liver
score
microvesicular
macrovesicular
steatosi
fatti
infiltr
zonal
niclosamid
treat
anim
variabl
degre
steatosi
rang
mean
steatosi
steatosi
score
tabl
contrast
sham
anim
typic
greater
steatosi
result
steatosi
score
tabl
similar
niclosamid
reduc
mean
percentag
steatosi
respect
result
steatosi
score
analog
includ
steatosi
steatosi
steatosi
steatosi
also
exhibit
reduc
steatosi
score
tabl
case
liver
close
resembl
liver
standard
chow
fed
mous
steatosi
despit
maintain
hfd
day
treatment
modest
effect
hepat
steatosi
compar
phenylbenzamid
test
steatosi
score
respect
old
anim
treat
ip
ip
timecours
day
day
anim
weigh
tissu
sampl
collect
standard
histolog
score
hepat
steatosi
autom
quantit
histomorphometr
score
use
standard
histolog
score
method
treat
anim
show
time
dose
depend
improv
steatosi
score
fig
addit
anim
show
gradual
declin
bodi
weight
howev
statist
signific
differ
observ
treatment
group
sham
anim
fig
use
aperio
scanscop
slide
scanner
scan
h
e
stain
slide
imag
analysi
quantif
macrovesicular
microvesicular
steatosi
use
approach
compar
effect
low
high
dose
hepat
steatosi
phenotyp
day
treatment
differ
observ
histolog
analysi
anim
treat
show
dose
depend
improv
steatot
phenotyp
score
dose
respect
quantit
analysi
use
alongsid
comprehens
manual
histolog
score
measur
chang
steatot
phenotyp
includ
chang
macrosteatosi
microsteatosi
lipid
droplet
size
zonal
lipid
distribut
lipid
droplet
count
addit
chang
hepat
steatosi
regularli
observ
coat
treat
anim
drier
consist
reduct
triglycerid
observ
mous
knockout
dri
coat
fig
anim
score
regard
oili
coat
phenotyp
repres
oili
coat
progress
drier
phenotyp
although
effect
difficult
quantifi
effect
greater
anim
other
gener
observ
chang
coat
appear
niclosamid
treat
anim
tabl
herein
report
develop
cellbas
highthroughput
assay
suitabl
identifi
compound
improv
fatti
liver
phenotyp
use
platform
identifi
sever
novel
phenylbenzamid
deriv
niclosamid
chemotyp
improv
hepat
steatosi
vitro
hfdfed
obes
mice
promin
fatti
liver
diseas
previou
studi
describ
abil
niclosamid
salt
form
treat
diabet
symptom
fatti
liver
mous
model
metabol
diseas
exact
mechan
underli
niclosamid
therapeut
effect
remain
unclear
studi
appear
associ
antihyperglycem
effect
abil
niclosamid
salt
uncoupl
oxid
phosphoryl
find
support
observ
sulfon
conjug
niclosamid
scn
deriv
nen
contain
sulfon
conjug
site
essenti
mitochondri
uncoupl
fail
improv
hyperglycemia
vivo
find
led
author
conclud
mitochondri
uncoupl
requir
antihyperglycem
activ
unfortun
studi
address
effect
scn
hepat
steatosi
remain
determin
whether
scn
niclosamid
deriv
uncoupl
oxid
phosphoryl
stimul
cellular
respir
improv
hepat
steatosi
independ
pathway
consist
idea
mook
et
al
recent
show
inhibit
wntbcatenin
signal
induc
niclosamid
analog
separ
uncoupl
oxid
phosphoryl
alter
cellular
atp
uncoupl
oxid
phosphoryl
lead
increas
oxygen
consumpt
without
concomit
rise
atp
product
niclosamid
salt
form
uncoupl
mammalian
mitochondria
high
nanomolar
concentr
increas
cellular
ocr
cell
without
stimul
hyperthermia
mitochondri
uncoupl
mechanist
may
lead
increas
energi
expenditur
lipid
oxid
well
lower
level
camp
requir
pka
mediat
hepat
glucagon
signal
interestingli
differ
energi
expenditur
bodi
weight
report
respons
niclosamid
salt
tao
et
al
report
increas
energi
expenditur
reduct
bodi
weight
chowdhuri
et
al
observ
chang
bodi
weight
energi
expenditur
rather
attribut
antihyperglycem
effect
decreas
hepat
glucos
product
result
abil
niclosamid
block
glucagon
signal
liver
requir
uncoupl
clear
hepat
steatosi
directli
test
studi
attenu
hepat
steatosi
improv
greasi
coat
phenotyp
high
fat
diet
fed
mice
effect
bodi
weight
histolog
score
steatosi
h
e
stain
whole
liver
section
bodi
weight
gram
b
hfdfed
mice
without
administr
ip
day
steatosi
score
use
autom
imag
analysi
pipelin
identif
macroand
microsteatosi
h
e
stain
whole
liver
section
c
tabul
lipid
droplet
statist
sham
vs
treat
liver
tissu
day
indic
statist
signific
differ
p
indic
statist
signific
differ
p
e
greasi
coat
phenotyp
old
hfdfed
mice
clear
greasi
coat
phenotyp
hfdfed
mice
treat
e
http
niclosamid
analog
attenu
obes
relat
chang
high
fat
diet
fed
mice
improv
diabet
outcom
focu
paper
hand
niclosamid
improv
glucos
toler
consist
previou
studi
show
improv
glucos
toler
absenc
chang
energi
expenditur
niclosamid
treatment
fig
synthes
screen
phenylbenzamid
deriv
niclosamid
chemotyp
test
abil
attenu
hepat
steatosi
vitro
approach
identifi
number
novel
compound
attenu
hepat
steatosi
vitro
vivo
low
nanomolar
rang
fail
increas
oxygen
consumpt
concentr
directli
test
uncoupl
oxid
phosphoryl
isol
mitochondria
increas
oxygen
consumpt
observ
niclosamid
nen
npp
submicromolar
concentr
find
suggest
may
possibl
sar
elucid
separ
effect
hepat
steatosi
potenti
mitochondri
uncoupl
activ
relat
effect
glucos
metabol
chang
bodi
weight
observ
administr
phenylbenzamid
deriv
howev
addit
experi
necessari
draw
conclus
regard
mitochondri
uncoupl
energi
expenditur
niclosamid
minim
absorb
gastrointestin
tract
lead
low
oral
bioavail
consequ
need
identifi
novel
deriv
improv
bioavail
treat
condit
may
requir
system
exposur
compound
could
provid
new
option
treat
divers
set
indic
includ
nafld
diabet
metabol
diseas
viral
infect
varieti
cancer
herein
report
bioavail
sever
compound
improv
achiev
balanc
polar
hydrophil
carboxyl
acid
group
nonpolar
lipophil
tertbutyl
group
exemplifi
halflif
niclosamid
hour
sever
phenylbenzamid
report
studi
show
improv
oral
bioavail
halflif
greater
hour
suggest
could
amen
daili
oral
deliveri
furthermor
number
compound
report
herein
greater
clogp
valu
significantli
improv
clogd
valu
compar
niclosamid
instanc
introduct
polar
surfac
area
methoxi
group
give
clogd
niclosamid
nen
accumul
predomin
liver
studi
need
explor
differ
affect
tissu
distribut
plasma
protein
bind
compound
report
studi
niclosamid
also
potenti
toxic
aromat
nitro
group
newli
report
compound
group
replac
carboxyl
acid
moieti
retent
activ
assay
although
niclosamid
good
safeti
profil
human
given
singl
oral
dose
niclosamid
lead
increas
sperm
head
abnorm
clastogen
effect
human
lymphocyt
frame
shift
mutat
salmonella
sp
unclear
effect
dna
becom
problemat
chronic
treatment
strategi
would
requir
treat
fatti
liver
diseas
diabet
herein
identifi
sever
compound
contrast
niclosamid
neg
ame
assay
measur
mutagen
togeth
factor
improv
pharmacokinet
properti
retent
import
biolog
activ
absenc
elev
respir
low
potenti
genotox
suggest
compar
niclosamid
may
better
therapeut
candid
treatment
nafld
diabet
niclosamid
test
panel
protein
kinas
concentr
inhibit
catenin
mtorc
notch
signal
pathway
significantli
inhibit
kinas
suggest
unlik
direct
inhibitor
kinas
recent
identifi
carbon
anhydras
caiii
one
three
influenc
gene
upregul
mice
respons
hfd
niclosamid
revers
caiii
upregul
similarli
note
phenylbenzamid
test
vivo
three
reduc
hepat
caiii
express
well
fa
suggest
caiii
may
suitabl
biomark
measur
benefici
effect
potenti
therapeut
hepat
steatosi
vivo
due
ampk
direct
role
inhibit
fatti
acid
synthesi
ampk
also
shown
promis
target
treatment
alcohol
nonalcohol
fatti
liver
diseas
highlyconserv
serin
threonin
kinas
regul
cellular
metabol
character
ampk
downstream
target
acetyl
coenzym
carboxylas
acc
ratelimit
enzym
energi
consumpt
de
novo
fatti
acid
synthesi
acc
directli
inhibit
ampk
phosphoryl
conserv
cellular
energi
niclosamid
nen
shown
activ
ampk
dose
timedepend
manner
result
increas
acc
phosphoryl
inhibit
mitochondri
beta
oxid
therefor
possibl
activ
ampk
compound
describ
herein
could
increas
lipid
oxid
downstream
phosphoryl
inhibit
acc
mitochondri
beta
oxid
consist
idea
identifi
sever
phenylbenzamid
associ
increas
respir
increas
phosphoryl
ampk
threonin
attenu
hepat
steatosi
liver
cell
may
suggest
compound
act
primarili
uncoupl
mitochondria
lead
activ
ampk
pathway
increas
lipid
oxid
similar
niclosamid
salt
form
contrast
also
identifi
sever
compound
attenu
hepat
steatosi
absenc
chang
oxygen
consumpt
rate
activ
ampk
pathway
vitro
may
possibl
compound
work
yet
undetermin
distinct
mechan
irrespect
mechan
action
compound
show
efficaci
hfdfed
obes
mous
model
attenu
hepat
lipid
accumul
conclus
niclosamid
present
number
potenti
challeng
becom
safe
effect
drug
extend
therapeut
use
effort
identifi
novel
compound
better
preclin
properti
retain
vivo
efficaci
treatment
hepat
steatosi
nafld
synthes
seri
novel
nsubstitut
phenylbenzamid
deriv
niclosamid
chemotyp
studi
describ
seri
novel
phenylbenzamid
deriv
improv
physicochem
pharmacokinet
characterist
attenu
hepat
steatosi
vitro
vivo
treatment
fatti
liver
nafld
furthermor
data
suggest
compound
might
separ
two
group
increas
respir
stimul
activ
ampk
pathway
group
equal
effect
attenu
hepat
steatosi
vitro
vivo
suggest
uncoupl
oxid
phosphoryl
requir
treatment
hepat
steatosi
particular
identifi
nsubstitut
phenylbenzamid
good
oral
bioavail
halflif
lack
genotox
stimul
respir
cell
suggest
compound
may
good
candid
clinic
develop
fatti
liver
diseas
support
inform
file
synthet
chemistri
procedur
docx
